Maurits de Brauw
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maurits de Brauw has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Sophie van Rijswijk
Department of Surgery, Spaarne Gasthuis, Hoofddorp, The Netherlands
2 shared publications - Victor E. A. Gerdes
Departments of Internal and Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands
2 shared publications A. S. Meijnikman
Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands
1 shared publicationA. W. van de Laar
Department of Surgery, Spaarne Gasthuis, Hoofddorp, The Netherlands
1 shared publication- Abraham S. Meijnikman
Departments of Internal and Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands
1 shared publication Albert K Groen
Amsterdam UMC, afd. Vasculaire Geneeskunde en Systeembiologie, Amsterdam
1 shared publication
Latest Publications
- 6 February 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (3) , 940-946
Variation in HbA1c in Patients with Obesity and type 2 Diabetes Mellitus 12 months after Laparoscopic One-Anastomosis Gastric Bypass and Laparoscopic Roux-en-Y Gastric Bypass: a Retrospective Matched Cohort Study
Background Glycemic control is an important goal of bariatric surgery in patients with type 2 diabetes mellitus (T2DM) and obesity. The laparoscopic one-anastomosis gastric bypass (OAGB) has potential metabolic benefits over the laparoscopic Roux-en-Y gastric bypass (RYGB). Aim of this study is to examine whether RYGB or OAGB grants better glycemic control 12 months post-surgery. Methods For this retrospective cohort study, patients with T2DM and obesity, who underwent primary OAGB between 2008 and 2017 were reviewed. For each OAGB patient, three primary RYGB patients were matched for age, gender and body mass index (BMI). Glycemic control was expressed by the glycated hemoglobin (HbA1c), which was measured pre- and 12 months post-operatively. Weight loss was reported in percentage total weight loss (%TWL). Results A total of 152 patients, of whom 38 had OAGB and 114 RYGB, were included. Mean (standard deviation (SD)) HbA1c was 7.49 (1.51)% in the OAGB group and 7.56(1.23)% in the RYGB group at baseline. Twelve months after surgery the mean (SD) HbA1c dropped to 5.73 (0.71)% after OAGB and 6.09 (0.76)% after RYGB (adjusted p = 0.011). The mean (SD) BMI was reduced from 42.5(6.3) kg/m2 to 29.6(4.7) kg/m2 after OAGB and 42.3(5.8) kg/m2 to 29.9 (4.5) kg/m2 after RYGB; reflecting 30.3 (6.8) %TWL post-OAGB and 29.0 (7.3) %TWL post-RYGB (p = 0.34). Conclusion This study indicates that OAGB leads to lower HbA1c one year after surgery compared to RYGB, without a difference in weight loss. Prospective (randomized) studies are needed to ascertain the most optimal metabolic treatment for patients with obesity and T2DM. Graphical abstract
- 6 February 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (3) , 940-946
Variation in HbA1c in Patients with Obesity and type 2 Diabetes Mellitus 12 months after Laparoscopic One-Anastomosis Gastric Bypass and Laparoscopic Roux-en-Y Gastric Bypass: a Retrospective Matched Cohort Study
Background Glycemic control is an important goal of bariatric surgery in patients with type 2 diabetes mellitus (T2DM) and obesity. The laparoscopic one-anastomosis gastric bypass (OAGB) has potential metabolic benefits over the laparoscopic Roux-en-Y gastric bypass (RYGB). Aim of this study is to examine whether RYGB or OAGB grants better glycemic control 12 months post-surgery. Methods For this retrospective cohort study, patients with T2DM and obesity, who underwent primary OAGB between 2008 and 2017 were reviewed. For each OAGB patient, three primary RYGB patients were matched for age, gender and body mass index (BMI). Glycemic control was expressed by the glycated hemoglobin (HbA1c), which was measured pre- and 12 months post-operatively. Weight loss was reported in percentage total weight loss (%TWL). Results A total of 152 patients, of whom 38 had OAGB and 114 RYGB, were included. Mean (standard deviation (SD)) HbA1c was 7.49 (1.51)% in the OAGB group and 7.56(1.23)% in the RYGB group at baseline. Twelve months after surgery the mean (SD) HbA1c dropped to 5.73 (0.71)% after OAGB and 6.09 (0.76)% after RYGB (adjusted p = 0.011). The mean (SD) BMI was reduced from 42.5(6.3) kg/m2 to 29.6(4.7) kg/m2 after OAGB and 42.3(5.8) kg/m2 to 29.9 (4.5) kg/m2 after RYGB; reflecting 30.3 (6.8) %TWL post-OAGB and 29.0 (7.3) %TWL post-RYGB (p = 0.34). Conclusion This study indicates that OAGB leads to lower HbA1c one year after surgery compared to RYGB, without a difference in weight loss. Prospective (randomized) studies are needed to ascertain the most optimal metabolic treatment for patients with obesity and T2DM. Graphical abstract
- Open Access
- 22 October 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-12
The effects of laparoscopic Roux-en-Y gastric bypass and one-anastomosis gastric bypass on glycemic control and remission of type 2 diabetes mellitus: study protocol for a multi-center randomized controlled trial (the DIABAR-trial)
Background: Metabolic surgery induces rapid remission of type 2 diabetes mellitus (T2DM). There is a paucity of high level evidence comparing the efficacy of the laparoscopic Roux-en-Y gastric bypass (RYGB) and the laparoscopic one-anastomosis gastric bypass (OAGB) in glycemic control. Also, the mechanisms that drive the conversion of T2DM in severe obese subjects to euglycemia are poorly understood.Methods: The DIABAR-trial is an open, multi-center, randomized controlled clinical trial with 10 years follow-up which will be performed in 220 severely obese patients, diagnosed with T2DM and treated with glucose-lowering agents. Patients will be randomized in a 1:1 ratio to undergo RYGB or OAGB. The primary outcome is glycemic control at 12 months follow-up. Secondary outcome measures are diverse and include weight loss, surgical complications, psychologic status and quality of life, dietary behavior, gastrointestinal symptoms, repetitive bloodwork to identify changes over time, glucose tolerance and insulin sensitivity as measured by mixed meal tests, remission of T2DM, presence of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in liver biopsy, oral and fecal microbiome, cardiovascular performance, composition of bile acids, and the tendency to develop gallstones.Discussion: The DIABAR-trial is one of the few randomized controlled trials primarily aimed to evaluate the glycemic response after the RYGB and OAGB in severe obese patients diagnosed with T2DM. Secondary aims of the trial are to contribute to a deeper understanding of the mechanisms that drive the remission of T2DM in severe obese patients by identification of microbial, immunological, and metabolic markers for metabolic response and to compare complications and side effects of RYGB and OAGB.Trial registration: ClinicalTrials.govNCT03330756; date first registered: October 13, 2017.
- 22 October 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-12
Open AccessThe effects of laparoscopic Roux-en-Y gastric bypass and one-anastomosis gastric bypass on glycemic control and remission of type 2 diabetes mellitus: study protocol for a multi-center randomized controlled trial (the DIABAR-trial)
Background: Metabolic surgery induces rapid remission of type 2 diabetes mellitus (T2DM). There is a paucity of high level evidence comparing the efficacy of the laparoscopic Roux-en-Y gastric bypass (RYGB) and the laparoscopic one-anastomosis gastric bypass (OAGB) in glycemic control. Also, the mechanisms that drive the conversion of T2DM in severe obese subjects to euglycemia are poorly understood.Methods: The DIABAR-trial is an open, multi-center, randomized controlled clinical trial with 10 years follow-up which will be performed in 220 severely obese patients, diagnosed with T2DM and treated with glucose-lowering agents. Patients will be randomized in a 1:1 ratio to undergo RYGB or OAGB. The primary outcome is glycemic control at 12 months follow-up. Secondary outcome measures are diverse and include weight loss, surgical complications, psychologic status and quality of life, dietary behavior, gastrointestinal symptoms, repetitive bloodwork to identify changes over time, glucose tolerance and insulin sensitivity as measured by mixed meal tests, remission of T2DM, presence of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in liver biopsy, oral and fecal microbiome, cardiovascular performance, composition of bile acids, and the tendency to develop gallstones.Discussion: The DIABAR-trial is one of the few randomized controlled trials primarily aimed to evaluate the glycemic response after the RYGB and OAGB in severe obese patients diagnosed with T2DM. Secondary aims of the trial are to contribute to a deeper understanding of the mechanisms that drive the remission of T2DM in severe obese patients by identification of microbial, immunological, and metabolic markers for metabolic response and to compare complications and side effects of RYGB and OAGB.Trial registration: ClinicalTrials.govNCT03330756; date first registered: October 13, 2017.
- 21 July 2022
- Vol. 166
[Laparoscopic cholecystolithotomy].
Laparoscopic cholecystectomy is the standard treatment for upper abdominal complaints in the presence of gallbladder stones. This operation is a mediocre solution since only 63 % of the operated patients the symptoms become symptom free after one year. The laparoscopic cholecystolithotomy is an alternative procedure for removal of gallstones while preserving the gallbladder. This technique is being performed in Asia, but not in Western countries. The technique seems promising in patients after a bariatric procedure. These patients have a temporarily increased incidence of gallbladder stones. Laparoscopic cholecystectomy is associated with a an increased complication rate in these patients. But also non bariatric patients with symptomatic gallbladder stones might benefit from a laparoscopic cholecystolithotomy.
- 21 July 2022
- Vol. 166
[Laparoscopic cholecystolithotomy].
Laparoscopic cholecystectomy is the standard treatment for upper abdominal complaints in the presence of gallbladder stones. This operation is a mediocre solution since only 63 % of the operated patients the symptoms become symptom free after one year. The laparoscopic cholecystolithotomy is an alternative procedure for removal of gallstones while preserving the gallbladder. This technique is being performed in Asia, but not in Western countries. The technique seems promising in patients after a bariatric procedure. These patients have a temporarily increased incidence of gallbladder stones. Laparoscopic cholecystectomy is associated with a an increased complication rate in these patients. But also non bariatric patients with symptomatic gallbladder stones might benefit from a laparoscopic cholecystolithotomy.
- Open Access
- 31 May 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (6) , 353
Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing, as are other manifestations of metabolic syndrome such as obesity and type 2 diabetes. NAFLD is currently the number one cause of chronic liver disease worldwide. The pathophysiology of NAFLD and disease progression is poorly understood. A potential contributing role for gut microbiome and metabolites in NAFLD is proposed. Currently, bariatric surgery is an effective therapy to prevent the progression of NAFLD and other manifestations of metabolic syndrome such as obesity and type 2 diabetes. This review provides an overview of gut microbiome composition and related metabolites in individuals with NAFLD and after bariatric surgery. Causality remains to be proven. Furthermore, the clinical effects of bariatric surgery on NAFLD are illustrated. Whether the gut microbiome and metabolites contribute to the metabolic improvement and improvement of NAFLD seen after bariatric surgery has not yet been proven. Future microbiome and metabolome research is necessary for elucidating the pathophysiology and underlying metabolic pathways and phenotypes and providing better methods for diagnostics, prognostics and surveillance to optimize clinical care.
- 31 May 2021
- Published by MDPI AG in Metabolites
- Vol. 11 (6) , 353
Open AccessGut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing, as are other manifestations of metabolic syndrome such as obesity and type 2 diabetes. NAFLD is currently the number one cause of chronic liver disease worldwide. The pathophysiology of NAFLD and disease progression is poorly understood. A potential contributing role for gut microbiome and metabolites in NAFLD is proposed. Currently, bariatric surgery is an effective therapy to prevent the progression of NAFLD and other manifestations of metabolic syndrome such as obesity and type 2 diabetes. This review provides an overview of gut microbiome composition and related metabolites in individuals with NAFLD and after bariatric surgery. Causality remains to be proven. Furthermore, the clinical effects of bariatric surgery on NAFLD are illustrated. Whether the gut microbiome and metabolites contribute to the metabolic improvement and improvement of NAFLD seen after bariatric surgery has not yet been proven. Future microbiome and metabolome research is necessary for elucidating the pathophysiology and underlying metabolic pathways and phenotypes and providing better methods for diagnostics, prognostics and surveillance to optimize clinical care.
- 16 March 2021
- Vol. 165
[Intensive lifestyle interventions: are they effective against obesity?]
The intensive lifestyle intervention (ILI) has recently become part of the reimbursed care in the Netherlands. What is the value of the ILI in the treatment of obesity and diabetes? Large clinical randomized studies on the effect of ILI showed a weight loss of more than 5% in selected patients, which could be partly sustained for several years. The ILI reduced risk factors without improving cardiovascular morbidity and mortality. The expensive clinical ILI had to be translated into an accessible and affordable primary care version. With this translation the effectiveness of the ILI has disappeared. With the current ILI, the weight loss is less than 5% and the health advantages are limited. It is foreseeable that the dismal results of the ILI will not generate enthusiasm among potential participants. The impact of ILI on the obesity epidemic will be very limited. Prevention will provide the way to go.
- 16 March 2021
- Vol. 165
[Intensive lifestyle interventions: are they effective against obesity?]
The intensive lifestyle intervention (ILI) has recently become part of the reimbursed care in the Netherlands. What is the value of the ILI in the treatment of obesity and diabetes? Large clinical randomized studies on the effect of ILI showed a weight loss of more than 5% in selected patients, which could be partly sustained for several years. The ILI reduced risk factors without improving cardiovascular morbidity and mortality. The expensive clinical ILI had to be translated into an accessible and affordable primary care version. With this translation the effectiveness of the ILI has disappeared. With the current ILI, the weight loss is less than 5% and the health advantages are limited. It is foreseeable that the dismal results of the ILI will not generate enthusiasm among potential participants. The impact of ILI on the obesity epidemic will be very limited. Prevention will provide the way to go.
- 26 March 2020
- Vol. 164
[Preferably a gastric sleeve operation].
One third of patients undergoing a gastric bypass operation will experience chronic abdominal symptoms. Diagnosis and treatment of this abdominal pain is a difficult task. The biggest problem is the ruling out of one of the possible causes of abdominal pain, such as internal herniation. Current diagnostic methods have generally not been successful in diagnosing internal herniation, and - more importantly - have not been able to rule out this diagnosis either. This leads to a high number of visits by these patients to the emergency department and outpatient clinic. Patients with pre-existing abdominal pain, or those who use analgesia preoperatively should preferably be treated by means of a gastric sleeve operation, instead of an operation involving anastomosis, such as a gastric bypass procedure.
- 26 March 2020
- Vol. 164
[Preferably a gastric sleeve operation].
One third of patients undergoing a gastric bypass operation will experience chronic abdominal symptoms. Diagnosis and treatment of this abdominal pain is a difficult task. The biggest problem is the ruling out of one of the possible causes of abdominal pain, such as internal herniation. Current diagnostic methods have generally not been successful in diagnosing internal herniation, and - more importantly - have not been able to rule out this diagnosis either. This leads to a high number of visits by these patients to the emergency department and outpatient clinic. Patients with pre-existing abdominal pain, or those who use analgesia preoperatively should preferably be treated by means of a gastric sleeve operation, instead of an operation involving anastomosis, such as a gastric bypass procedure.